RT Book, Section A1 Akamine, Christine A1 Clark, Eva A1 Shandera, Wayne X. A2 Papadakis, Maxine A. A2 McPhee, Stephen J. A2 Rabow, Michael W. A2 McQuaid, Kenneth R. SR Print(0) ID 1193135139 T1 Major Vaccine-Preventable Viral Infections T2 Current Medical Diagnosis & Treatment 2023 YR 2023 FD 2023 PB McGraw-Hill Education PP New York, NY SN 9781264687343 LK accessmedicine.mhmedical.com/content.aspx?aid=1193135139 RD 2024/03/29 AB Key Clinical Updates in Major Vaccine-Preventable Viral InfectionsA novel oral polio vaccine type 2 (nOPV2) has been developed in response to the ongoing circulating vaccine-derived type 2 poliovirus outbreaks and has been shown to be safe and immunogenic in previously immunized adults. Studies have shown that nOPV2 is more genetically stable than the mOPV2 and therefore less prone to reverting to neurovirulence. The nOPV2 was recommended for initial use under the World Health Organization’s Emergency Use Listing Procedure in November 2020.Coster ID et al. Lancet. [PMID: 33308429]